Sonoma Pharmaceuticals, Inc. (SNOA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on June 18, 2026. The filing addresses an update to an At Market Issuance Sales Agreement entered into on September 26, 2025, with Ladenburg Thalmann & Co. Inc. as the sales agent.
Key Financial Metrics and Capital Activity
- Capital Raised: From September 26, 2025, through June 18, 2026, the Company sold 173,073 shares of common stock for an aggregate purchase price of $574,633.
- Offering Capacity: The aggregate offering price available under the registration statement has been increased to $3,641,703.
- Unsold Capacity: As of the filing date, $1,495,830 of previously registered shares remained unsold and were included in the new aggregate offering limit.
- Financial Statements: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these operational financial indicators.
Material Changes
The primary material change is the amendment of the Prospectus Supplement to increase the total amount of common stock that may be offered and sold under the At Market Issuance Sales Agreement from the original $2,070,463 to $3,641,703.
Outlook, Risks, and Management Commentary
Management has executed a supplement to the Prospectus Supplement to expand the Company's ability to raise capital through the existing sales agreement. The filing includes a legal opinion from Polsinelli PC regarding the validity of the shares to be issued. No specific forward-looking guidance, risk factors, or unusual items were detailed in this specific report beyond the standard securities law disclaimers.
Key Facts for Investor Verification
- Verify the current market price of SNOA common stock to assess the dilution impact of the remaining $3.07 million in available offering capacity.
- Confirm the total number of shares outstanding post-issuance of the 173,073 shares sold under the agreement.
- Review the full text of the At Market Issuance Sales Agreement (Exhibit 1.1) for commission rates and termination clauses.
- Check subsequent filings for any additional sales executed under the increased $3,641,703 limit.